Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe First People's Hospital of Changzhou
About this trial
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.
Eligibility criteria
Qualifiers
Subjects with documented histologically confirmed primary grade 4 advanced malignant glioma.
No more than 3 prior relapses or prior systemic treatments.
Recurrent disease documented by MRI after prior therapy.
Completed at least one full cycle of temozolomide of 200 mg/m2/day administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression.
Disqualifiers
Progressed while on temozolomide.
Evidence of acute intracranial or intratumoral hemorrhage > Grade 1.
Not recovered from the toxic effects of prior therapy.
Pregnant or breast feeding.
Trial design
Treatments tested in this trial
- Temozolomide
- CIK
Treatment groups
120 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov